In NSCLC and TNBC human tumor xenograft-bearing mice treated with a saturating dose of all anti-PD-L1 mAbs (atezolizumab, avelumab, and durvalumab), a significantly reduced [64Cu]WL12 uptake was observed compared to saline treated controls (Figure 4). This evidence concerns the gene CD274 and non-small cell lung carcinoma.